A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 577 participants.
Also called NCT01621178
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 577 participants
- Sponsor
- Registry
-
NCT01621178 -
2012-000829-44
-
- Other papers using this trial's data
- Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Brazil, Hungary, Mexico, Poland, Romania, South Africa, Spain, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT01621178. Randomized; no masking; primary purpose treatment. Start 2012-07 (registry gives no type); primary completion 2016-06 (actual). Results posted on 2017-07-24.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
- Acronym
- AWARD-7
- Condition
- Type 2 Diabetes
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- Dulaglutide
- Intervention (Drug)
- Insulin glargine
- Intervention (Drug)
- Insulin lispro
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01621178- Content hash
bc227bb26e6e25b1d77de11b004426a71e775825ae44e46b97c8d23439a8b78d